Vemurafenib
Sign in to save this workspacePrimary targets: BRAF · FDA status: FDA Approved
Selectivity scorecard
KISS
96.49
Gini
0.598
CATDS
0.011
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Vemurafenib. Strongest target: LCK at 98.4% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | LCK | 98.4% | 1.6% |
| 2 | KHS_MAP4K5 | 98.3% | 1.7% |
| 3 | MEK2 | 98.1% | 1.9% |
| 4 | BRK | 98.0% | 2.0% |
| 5 | ARAF | 96.9% | 3.1% |
| 6 | MYLK4 | 95.8% | 4.2% |
| 7 | SRMS | 95.3% | 4.7% |
| 8 | RAF1 | 95.2% | 4.8% |
| 9 | RIPK3 | 94.5% | 5.5% |
| 10 | MEK5 | 94.4% | 5.6% |
| 11 | TNIK | 94.4% | 5.6% |
| 12 | FGR | 93.6% | 6.4% |
| 13 | ZAK_MLTK | 92.9% | 7.1% |
| 14 | BRAF | 92.8% | 7.2% |
| 15 | MLCK2_MYLK2 | 89.6% | 10.4% |
| 16 | DDR2 | 89.4% | 10.6% |
| 17 | MST1_STK4 | 89.0% | 11.0% |
| 18 | WNK3 | 88.5% | 11.5% |
| 19 | BLK | 87.8% | 12.2% |
| 20 | TGFBR2 | 86.4% | 13.6% |
Selectivity landscape
Where Vemurafenib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Vemurafenib.
Annotations
Sign in to read and post annotations.
Loading…